POLE2

Across TCGA pan-cancer cohorts, POLE2 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated POLE2 data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher POLE2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated POLE2 expression acts as an unfavorable survival marker.

BRCA, THYM, and LAML are the cancer types where POLE2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	DFS	Median	All	0.433	0.903	.001	22	view →
THYM	OS	Median	All	0.186	0.931	<.001	15	view →
LAML	DFS	Median	All	0.028	0.572	<.001	12	view →
LUSC	OS	Median	II,III,IV	0.259	0.742	.021	12	view →
SKCM	OS	Median	II,III,IV	0.174	0.731	<.001	12	view →
LIHC	DFS	Median	II,III,IV	0.044	0.427	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

POLE2–BRCA (DFS)

Open the BRCA breakdown →